(Reuters) - Cancer diagnostics company Exact Sciences Corp <EXAS.O> is in advanced negotiations to buy healthcare company Genomic Health Inc <GHDX.O> for about $2.8 billion to strengthen its cancer ...
MADISON, Wis. - Exact Sciences Corp. (NASDAQ: NASDAQ:EXAS), a prominent cancer screening and diagnostics company, announced today that the U.S. Food and Drug Administration (FDA) has approved the ...
Exact Sciences Corp. (NASDAQ: EXAS) is on a self-proclaimed mission to change the way cancer is detected and treated. The Madison, Wisconsin company is among the market’s best price performers, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback